Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
ViiV Healthcare and GlaxoSmithKline are jointly developing GSK3640254.
ViiV alleges that the bictegravir component of the tablet infringes on its own patent for Tivicay (dolutegravir).
Deborah Waterhouse will lead the global HIV pharma company.
The sale includes an HIV attachment inhibitor called fostemsavir and a maturation inhibitor, both in late-stage development.
ViiV Healthcare has announced plans to acquire the portfolio of HIV antiretrovirals Bristol-Myers Squibb has in development.
Cutting through the hype and hyperbole.
GSK (GlaxoSmithKline) has teamed up with the University of North Carolina at Chapel Hill to pursue HIV cure strategies.
GlaxoSmithKline (GSK) has joined with University of North Carolina at Chapel Hill to pursue HIV cure strategies.
Pharma giant GlaxoSmithKline (GSK) might plan an initial public offering (IPO) of a minority stake in ViiV Healthcare, which makes new HIV med...
A potential juror was wrongly removed because he is gay.
A unanimous decision held a potential juror was wrongly removed because he is gay.
Several changes are intended to improve its transparency.
A new fund allows investors to finance late-stage global health technologies in low-income countries.
Race and gender cannot be used as reasons to remove potential jurors.
The FDA has approved ViiV Healthcare’s HIV med Tivicay (dolutegravir), the second approved antiretroviral (ARV) in the integrase strand...
Advocates from the Treatment Action Group (TAG) explain why results of clinical trials should be more transparent.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.